Treatment of ANCA-associated vasculitis

Nature Reviews Nephrology

Volumn 10, Issue 1, 2014, Pages 25-36

  Schönermarck, Ulf ^a   Gross, Wolfgang L ^b   De Groot, Kirsten ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Klinikum Offenbach GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ANCA ASSOCIATED VASCULITIS; EOSINOPHILIC GRANULOMA; GRANULOMATOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; REMISSION; REVIEW; SURVIVAL; TREATMENT DURATION; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION;

EID: 84890798253     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.225     Document Type: Review

References (92)

1. Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1-11 (2013).
2. Jennette, C. J. & Falk, R. J. L. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. Presse Med. 42, 493-498 (2013).
3. Pepper, R. J. & Salama, A. D. Classifying and predicting outcomes in ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 27, 2135-2137 (2012).
4. Jayne, D. L27. Antibodies versus phenotypes: a clinician's view. Presse Med. 42, 579-582 (2013).
5. Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214-223 (2012).
6. Hoffman, G. S., Leavitt, R. Y., Kerr, G. S. & Fauci, A. S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 35, 1322-1329 (1992).
7. Slot, M. C., Tervaert, J. W., Boomsma, M. M. & Stegeman, C. A. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 51, 269-273 (2004).
8. Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036-1043 (2010).
9. Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488-494 (2011).
10. Wall, N. & Harper, L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat. Rev. Nephrol. 8, 523-532 (2012).
11. Holle, J. U. et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 63, 257-266 (2011).
12. Hilhorst, M. et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol. Dial. Transplant. 28, 373-379 (2013).
13. Walton, E. W. Giant cell granuloma of the respiratory tract (Wegener's Granulomatosis). BMJ 2, 265-270 (1958).
14. Hoffman, G. S. et al. Wegener's granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488-498 (1992).
15. Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955-960 (2012).
16. de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670-680 (2009).
17. Neumann, I. et al. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol. Dial. Transplant. 20, 96-104 (2005).
18. de Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461-2469 (2005).
19. Faurschou, M. et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472-3477 (2012).
20. Faurschou, M. et al. Reply. Arthritis Rheum. 65, 844 (2013).
21. Langford, C. A. & Hoffman, G. S. Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al. Arthritis Rheum. 65, 843 (2013).
22. Jones, R. B. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: "MYCYC". On behalf of the European vasculitis study group [abstract]. Presse Med. 42, 678-679 (2013).
23. Casian, A. & Jayne, D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr. Opin. Rheumatol. 23, 12-17 (2011).
24. Jayne, D. R. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180-2188 (2007).
25. Walsh, M. et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 84, 397-402 (2013).
26. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00987389 (2013).
27. Pepper, R. J. et al. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 8, 219-224 (2013).
28. Szpirt, W. M., Heaf, J. G. & Petersen, J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis- A clinical randomized controlled trial. Nephrol. Dial. Transplant. 26, 206-213 (2011).
29. Walsh, M. et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am. J. Kidney Dis. 57, 566-574 (2011).
30. Casian, A. & Jayne, D. Management of alveolar hemorrhage in lung vasculitides. Semin. Respir. Crit. Care Med. 32, 335-345 (2011).
31. Hruskova, et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand. J. Rheumatol. 42, 211-214 (2013).
32. Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220 (2010).
33. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
34. Jones, R. B., Walsh, M. & Jayne, D. R. Two year follow up results from a randomised trial of RTX versus CyP for ANCA-associated vasculitis: RITUXVAS [abstract]. Clin. Exp. Immunol. 164, 57 (2011).
35. Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417-427 (2013).
36. Miloslavsky, E. M. et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 65, 2441-2449 (2013).
37. Clain, J. M. & Specks, U. S. Rituximab for ANCA-associated vasculitis: the experience in the United States. Presse Med. 42, 530-532 (2013).
38. Walsh, M., Merkel, P. A., Mahr, A. & Jayne, D. The effects of duration of glucocorticoid therapy on relapse rate in anti-neutrophil cytoplasm antibody associated vasculitis: a meta-analysis. Arthritis Care Res. 62, 1166-1173 (2010).
39. Cohen Tervaert, J. W. Rituximab in ANCA-associated vasculitis: a revolution? Nephrol. Dial. Transplant. 26, 3077-3079 (2011).
40. Mansfield, N. et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol. Dial. Transplant. 26, 3280-3286 (2011).
41. Guerry, M. J. et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51, 634-643 (2012).
42. Jones, R. B. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156-2168 (2009).
43. Martinez Del Pero, M. et al. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin. Otolaryngol. 34, 328-335 (2009).
44. Hamour, S. M. & Salama, A. D. ANCA comes of age-but with caveats. Kidney Int. 79, 699-701 (2011).
45. Bomback, A. S. et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 79, 757-764 (2011).
46. Pagnoux, C. et al. Treatment of systemic necrotizing vasculitides in patients >65 years old: results of the multicentre randomized CORTAGE trial [abstract]. Presse Med. 42, 679-680 (2013).
47. Holle, J. U. et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann. Rheum. Dis. 69, 1934-1939 (2010).
48. Pagnoux, C. et al. Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J. Rheumatol. 38, 475-478 (2011).
49. DeRemee, R. A., McDonald, T. J. & Weiland, L. H. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin. Proc. 60, 27-32 (1985).
50. DeRemee, R. A. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum. 31, 1068-1074 (1988).
51. Reinhold-Keller, E. et al. Response to trimethroprim-sulfamethoxazole (T/S) in Wegener's granulomatosis (WG) depends on the phase of disease. QJM 89, 15-23 (1996).
52. Kallenberg, C. G. & Tadema, H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to "autoimmunity and infection". Autoimmun. Rev. 8, 29-32 (2008).
53. Hellmich, B. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66, 605-617 (2007).
54. Rutgers, A. & Kallenberg, C. G. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr. Opin. Rheumatol. 24, 245-251 (2012).
55. Holle, J. U. et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann. Rheum. Dis. 71, 327-333 (2012).
56. Jayne, D. R. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93, 433-439 (2000).
57. Martinez, V. et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 58, 308-317 (2008).
58. Mukhtyar, C. et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 67, 1004-1010 (2008).
59. Booth, A. D. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776-784 (2003).
60. Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 542-548 (2012).
61. Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310-317 (2009).
62. Lapraik, C. et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46, 1615-1616 (2007).
63. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003).
64. Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790-2803 (2008).
65. Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381-2388 (2010).
66. WGET Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351-361 (2005).
67. Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1087-1091 (2007).
68. European Vasculitis Study Group. Clinical Trial Protocol: REMAIN. [online], http://www.vasculitis.nl/media/documents/remain.pdf (2006).
69. Little, M. A. et al. Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 17, 160-169 (2006).
70. Cartin-Ceba, R. et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 64, 3770-3778 (2012).
71. Rhee, E. P., Laliberte, K. A. & Niles, J. L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol. 5, 1394-1400 (2010).
72. Smith, R. M. et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760-3769 (2012).
73. van Vollenhoven, R. F. et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37, 558-567 (2010).
74. van Vollenhoven, R. F. et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. (2012).
75. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00748644 (2013).
76. Charles, P. & Guillevin, L. S. Rituximab for ANCA-associated vasculitides: the French experience. Presse Med. 42, 534-536 (2013).
77. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01697267 (2013).
78. Stegeman, C. A., Cohen Tervaert, J. W., De Jong, P. E. & Kallenberg, C. G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335, 16-20 (1996).
79. Zycinska, K., Wardyn, K. A., Zielonka, T. M., Krupa, R. & Lukas, W. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur. J. Med. Res. 14 (Suppl. 4), 265-267 (2009).
80. Pagnoux, C. et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908-2918 (2008).
81. Pierrot-Deseilligny Despujol, C., Pouchot, J., Pagnoux, C., Coste, J. & Guillevin, L. Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49, 2181-2190 (2010).
82. Stegeman, A. C. et al. Association of chronic nasal carriage of staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann. Intern. Med. 120, 12-17 (1994).
83. Boomsma, M. M. et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43, 2025-2033 (2000).
84. Birck, R., Schmitt, W. H., Kaelsch, I. A. & van der Woude, F. J. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am. J. Kidney Dis. 47, 15-23 (2006).
85. Finkielman, J. D. et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 147, 611-619 (2007).
86. Tomasson, G., Grayson, P. C., Mahr, A. D., Lavalley, M. & Merkel, P. A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis- A meta-analysis. Rheumatology (Oxford) 51, 100-109 (2012).
87. Faurschou, M. et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100-105 (2008).
88. Lamprecht, P., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41, 1303-1307 (2002).
89. Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J. & Nachman, P. H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. 20, 2725-2732 (2005).
90. Birck, R. et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 14, 440-447 (2003).
91. Schmitt, W. H., et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440-1448 (2004).
92. Metzler, C., Fink, C., Lamprecht, P., Gross, W. L. & Reinhold-Keller, E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43, 315-320 (2004).